USNA, US90328M1071

USANA expands Utah partnership: what it means for USANA Health Sciences stock

Published on 10/07/2026 at 07:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

For USANA Health Sciences stock, the partnership means access to more than 500 athletes. Second-quarter sales were USD 223.0 million and diluted EPS was minus USD 1.16.

USNA, US90328M1071, Illustration mit AI erstellt.
USNA, US90328M1071, Illustration mit AI erstellt.

USANA Health Sciences, Inc. (ISIN US90328M1071) announced a partnership with Utah Athletics supporting more than 500 student-athletes across 19 sports on October 6, 2026. For USANA Health Sciences stock, the agreement adds a local marketing and athlete-support platform while the company manages a sharply weaker second-quarter result.

Utah deal reaches 500 athletes

According to University of Utah Athletics on October 6, 2026, USANA will provide nutritional products, name-image-likeness opportunities and community support for more than 500 student-athletes. The program covers 19 sports and extends USANA's existing athlete partnerships to its Salt Lake City home market.

The commercial value is indirect rather than a disclosed contract amount. The agreement gives USANA a branded connection to a university sports program, while the operating figures show why any marketing benefit must be weighed against near-term profitability.

Second-quarter loss changes the picture

USANA Health Sciences reported second-quarter 2026 net sales of USD 223.0 million and diluted earnings per share of minus USD 1.16 for the quarter ended July 4, 2026. Simply Wall St reported that revenue declined 5.3 percent from the second quarter of 2025, when USANA posted earnings per share of USD 0.52.

That comparison is the key operating counterweight to the Utah announcement. A wider athlete network can support visibility, but the second-quarter figures point to a business that still needs sales stabilization before promotional expansion becomes financially decisive.

Credit covenant sets a hard hurdle

USANA amended its revolving credit agreement on September 30, 2026. As reported by StockTitan, the USD 75.0 million facility now requires at least USD 100.0 million of Consolidated EBITDA over each trailing four-fiscal-quarter period beginning with the quarter ending October 3, 2026. The threshold falls to USD 70.0 million when lender exposure is USD 50.0 million or less.

The amendment also raises the annual asset-sale limit from USD 500,000 to USD 2.5 million and permits a sale of USANA Australia's Sydney property. Together, those terms give the balance sheet more flexibility while placing a measurable profitability hurdle ahead of the next reporting cycle.

USNA market value remains small

USANA's market capitalization was USD 273.8 million as of October 6, 2026. The 52-week range was USD 12.57 to USD 26.76, a spread that puts the operating update in the context of a small-cap stock with a wide recent trading history.

The company is scheduled to report third-quarter 2026 results on October 28, 2026, according to MarketBeat. That report should put the USD 100.0 million covenant threshold and the USD 219.02 million consensus revenue figure into the next measurable test.

USANA Health Sciences stock facts

  • Company: USANA Health Sciences, Inc.
  • ISIN: US90328M1071
  • Ticker: USNA
  • Primary exchange: New York Stock Exchange
  • Market capitalization: USD 273.8 million as of October 6, 2026
  • 52-week range: USD 12.57-26.76 as of October 6, 2026
  • Sector / Industry: Consumer Defensive / Packaged Foods

More news and analysis on USANA Health Sciences stock

Disclaimer...

en | US90328M1071 | USNA | boerse | 70250906 | bgmi